Pulmonx Co. (NASDAQ:LUNG – Get Free Report) Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total transaction of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares of the company’s stock, valued at $8,995,869.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Pulmonx Stock Performance
LUNG stock opened at $8.58 on Friday. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $14.84. The firm’s 50-day moving average is $7.23 and its 200 day moving average is $7.62. The company has a market capitalization of $333.04 million, a PE ratio of -5.57 and a beta of 0.63. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92.
Pulmonx (NASDAQ:LUNG – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.02. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. On average, research analysts anticipate that Pulmonx Co. will post -1.64 EPS for the current year.
Institutional Investors Weigh In On Pulmonx
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on LUNG shares. Wells Fargo & Company lowered their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Lake Street Capital assumed coverage on shares of Pulmonx in a research note on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Canaccord Genuity Group upped their target price on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.
Get Our Latest Stock Report on Pulmonx
Pulmonx Company Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Read More
- Five stocks we like better than Pulmonx
- Why is the Ex-Dividend Date Significant to Investors?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What are earnings reports?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Best Stocks Under $5.00
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.